China-based HighTide Therapeutics Inc. has announced the completion of Series C and C+ financing rounds, raising a total of USD 107 million. The financing was led by the TCM Healthcare Fund of Guangdong, managed by China Development Bank Capital, with participation from Yuexiu Fund and Yuthai Fund. The proceeds will be used to accelerate multiple global development programs, including mid-to-late-stage clinical trials, and the commercialization and business development of the company’s robust pipeline.
Company Overview and Pipeline
HighTide Therapeutics is a globally integrated clinical-stage biopharmaceutical company focused on the discovery and development of novel multifunctional therapies for metabolic and digestive diseases with significant unmet medical needs. The company’s lead drug candidate, HTD1801, is a first-in-class new molecular entity currently in clinical development for the treatment of type 2 diabetes (T2DM), nonalcoholic steatohepatitis (NASH), severe hypertriglyceridemia (SHTG), and primary sclerosing cholangitis (PSC). The US FDA has granted Fast Track designation to HTD1801 for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program.
Future Outlook
The successful completion of the Series C and C+ financing rounds positions HighTide Therapeutics to significantly advance its global development programs. With robust financial backing and a strong pipeline of innovative therapies, HighTide is poised to make a meaningful impact in addressing significant unmet needs in metabolic and digestive diseases. The company’s ongoing efforts in clinical development highlight its dedication to improving patient outcomes through novel treatments.-Fineline Info & Tech
